Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2021-04-29 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science today announced that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint
Regulatory Filings Classification · 1% confidence The document is explicitly titled "**PRESS RELEASE**" and announces a significant clinical trial result: "PHASE 2B/3 STUDY EVALUATING MASITINIB IN IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC) MET ITS PRIMARY ENDPOINT". This format—a brief, high-level announcement of results, often accompanied by contact information for media and investors—is characteristic of an Earnings Release (ER) or a general press release regarding corporate news. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, the most appropriate classification for an initial announcement of key operational/clinical news is 'Earnings Release' (ER), as clinical trial milestones often drive investor interest similarly to earnings announcements. It is not an RPA because it contains substantial content about the study and the drug, not just an announcement that a report is available.
2021-04-29 English
AB Science secures 6M€ in non-dilutive financing guaranteed by the French Government
Capital/Financing Update Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces that AB Science has secured EUR 6 million in non-dilutive financing guaranteed by the French government (PGE loans). This event relates directly to the company's financial structure and fundraising activities. Based on the provided definitions, the category 'Capital/Financing Update' (CAP) is the most appropriate fit for an announcement detailing new debt financing secured by the company.
2021-04-14 English
AB Science obtient un financement non dilutif de 6M€ garanti par l'Etat Français
Capital/Financing Update Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that AB Science has secured 6 million Euros in non-dilutive financing guaranteed by the French State (PGE - Prêt Garanti par l'État). This announcement details a specific corporate financing activity, including the amount, the lenders (Société Générale, Bpifrance, Banque Populaire), and the terms (maturity, guarantee percentage). This directly aligns with the definition of 'Capital/Financing Update' (Code: CAP), which covers company fundraising and financing activities. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it pertains to a specific financing event.
2021-04-14 French
AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19
Regulatory Filings Classification · 1% confidence The document is explicitly titled "**PRESS RELEASE**" and announces a collaboration between AB Science and the University of Chicago regarding research for COVID-19 treatment using masitinib. This format, focusing on a specific, timely corporate event (a new research agreement/collaboration), is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing a significant business development rather than a formal financial report (like 10-K or IR) or a specific regulatory disclosure (like DIRS or DIV), it fits best under the general announcement category. Given the options, 'ER' (Earnings Release) is often used for major business updates accompanying financial periods, but since this is purely a business/research announcement, 'RNS' (Regulatory Filings - general/miscellaneous) is the most appropriate fallback for a non-standard, material press release that isn't a core financial report or a specific transaction notice. However, in many databases, major non-financial press releases are often categorized alongside ERs if they are material news. Given the content is a major business development announcement, and it is not a formal financial report, RNS is the safest general classification, but ER is also plausible if the database uses ER broadly for material news. I will select RNS as the best fit for a general, material press release that isn't a financial report or a specific transaction.
2021-04-06 English
AB Science annonce aujourd’hui la signature d'un accord de licence exclusif avec l'Université de Chicago sur la prévention et le traitement de la Covid-19
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a research collaboration between AB Science and the University of Chicago regarding Masitinib for COVID-19 treatment. It details the terms of the agreement, scientific findings, and quotes from researchers and management. This type of announcement, focusing on a specific business development (a research partnership and licensing agreement) rather than routine financial reporting (like 10-K, ER, or IR), is best classified as a general corporate announcement. Since it does not fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), and it is not a transcript (CT) or a formal regulatory filing like a proxy (PSI) or annual report (10-K), the most appropriate general category for a significant, non-standard corporate update is Regulatory Filings (RNS), which serves as a broad category for miscellaneous regulatory announcements not covered elsewhere. Given the content is a press release announcing a strategic partnership, RNS is the best fit among the provided options.
2021-04-06 French
AB Science communique ce jour une mise à jour du calendrier des résultats finaux de son étude de phase 3 du masitinib (AB12003) dans le traitement du cancer de la prostate métastatique
Report Publication Announcement Classification · 1% confidence The document is a press release dated March 31, 2021, from AB Science SA, providing an update on the timeline for the final results of its Phase 3 clinical study for Masitinib (AB12003) in metastatic castration-resistant prostate cancer (mCRPC). It explicitly states that the final results will be available in April 2021. This structure—an announcement about the timing or release of financial/study results, rather than the full results or a comprehensive report—strongly indicates a Report Publication Announcement (RPA). It is not a full Annual Report (10-K), an Interim Report (IR), or a Call Transcript (CT). It fits the definition of announcing the publication of future information.
2021-03-31 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.